Loading
Zevra Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$671M
No insider purchase over the last 90 days. The latest was filed 16 Sept 2025.
Zevra Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Zevra Therapeutics, Inc. as filed with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 18 filings signed by 11 insiders.
The flow runs one way only: 5 sales worth €837k, from 5 insiders, and no purchase. One trade stands out by size: a sale of €411k from Thompson Rahsaan, disclosed on 17 August 2026, or 0.071% of market capitalisation.
Compared with its exchange (5,458 companies, median 22 filings), a count of 18 filings is below the norm. Over the whole record (from 2016), the tally stands at 47 purchases and 10 sales.
Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
80
Thresholds
n/a
Buy Volume
€910,068
47 ops. · all time
Sell Volume
€2M
10 ops. · all time
Who traded when
BuySaleCorey Michael Watton1 buy1 sale
John B. Bode2 buys
Joshua Schafer2 sales
Neil F. McFarlane2 sales
Rahsaan Thompson2 sales
Timothy J. Sangiovanni2 sales
+3 other insiders
Since the insiders bought
- +35.6%Entry US$7.33 · Close 16 Oct 2026 US$9.94
- +36.9%Entry US$7.26 · Close 16 Oct 2026 US$9.94
- +24.8%Entry US$9.51 · Close at T+365 US$11.87
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,154 of 24,148 companies
79.0
score / 100
Value68
Quality90
FCF yld-0.4%
Earn yld12%
EV/EBITDA7.4x
ROE35%
Gross mgn85%
Net mgn78%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.30
Analyst consensus
9 analysts1.22/5
US$20.00Target US$25.00(+121%)US$35.00
Income statement
RevenueUS$106.5M
Gross profitUS$90M85% margin
EBITDAUS$98.7M93% margin
Net incomeUS$83.2M42.8% margin
Valuation
PER (trailing)12.2x
PER (forward)10.5x
P/Book3.1x
Beta0.95
Balance sheet & cash
Market capUS$671M
Total debtUS$63.2M
Free Cash Flow-US$2.4M
Debt / Equity1%
Profitability & ownership
ROE34.8%
ROA8.7%
% insiders1.3%
% institutions77.3%
Last declaration on 13 October 2026
Declarations80 total
20,000 shares@ US$11.390.034% mcap100.0% of flowCommonSEC144:0001950047-26-010170
50,000 sharesCommon StockSEC:0001434647-26-000075:0
20,000 shares@ US$11.24740.033% mcap30.2% of flowCommon StockSEC:0001434647-26-000075:1
42,666 shares@ US$11.12770.071% mcap68.5% of flowCommon StockSEC:0001434647-26-000073:0
42,666 shares@ US$11.180.072% mcap100.0% of flowCommonSEC144:0001950047-26-008134
12,300 shares@ US$4.970.0092% mcap28.8% of flowCommon StockSEC:0001434647-26-000070:0
12,300 shares@ US$11.25020.021% mcap65.3% of flowCommon StockSEC:0001434647-26-000070:1
39,200 shares@ US$4.9743.2% of flowCommon StockSEC:0001612084-26-000002:0
37,500 sharesCommon StockSEC:0001681098-26-000004:0
10,500 shares@ US$9.190546.2% of flowCommon StockSEC:0001945557-26-000004:0
3,000 shares@ US$9.182746.4% of flowCommon StockSEC:0001698328-26-000004:0
11,333 sharesCommon StockSEC:0001788524-26-000002:0
11,333 sharesCommon StockSEC:0001945557-26-000002:0
11,333 sharesCommon StockSEC:0001910132-26-000002:0
6,333 sharesCommon StockSEC:0001698328-26-000002:0
233,334 sharesCommon StockSEC:0001681098-26-000002:0
140,667 shares0Common StockSEC:0001488774-26-000002:0
50,000 sharesCommon StockSEC:0001681098-25-000005:0
3,175 shares@ US$7.7852100.0% of flowCommon StockSEC:0001288232-25-000009:0
Canonical exit: 11 Dec 2025 (T+90)
20,000 shares@ US$7.89100.0% of flowCommon StockSEC:0001610064-25-000011:0
Canonical exit: 11 Dec 2025 (T+90)
5,000 shares@ US$9.16510.1% of flowCommon StockSEC:0001437749-25-027456:0
Canonical exit: 17 Nov 2025 (T+90)
24,000 shares@ US$9.208531.5% of flowCommon StockSEC:0001437749-25-021577:0
66,666 sharesCommon StockSEC:0001437749-25-021183:0
300 shares@ US$7.83841.2% of flowCommon StockSEC:0001437749-25-010332:0
Canonical exit: 26 Jun 2025 (T+90)
25 of 80 declarations
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a company focused on developing treatments for rare diseases and psychiatric disorders. It is listed on NASDAQ under the ticker ZVRA.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
